|
186 Products |
| 186 Products |
|
1696 Diseases |  |
95004 News |  |
| «12...118119120121122123124125126127128...10651066» |
- prednisone / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
Epidemiology and Predictors of Relapse in Giant Cell Arteritis: Results of the ARTESER Register (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_4369;
Between 8 and 18% of patients had multiple relapses. Despite the relevance of this problem, we do not yet have any predictive factors to identify patients with a higher risk of flare.
- Olumiant (baricitinib) / Incyte, Eli Lilly, Rinvoq (upadacitinib) / AbbVie
Safety and Effectiveness in Cycling Between Non-Selective and Selective JAKi in a Multi-Center Registry of Rheumatoid Arthritis in the Middle East (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_4119;
We evaluated the overall safety of JAKis in the Middle Eastern population, as well as the clinical efficacy of cycling from Tofacitinib (Tofa) or Baricitinib (Bari) to Upadacitinib (Upa)...All patients had previously received csDMARD, however 56% received bDMARD and 59% received oral prednisolone... Our findings show that switching from non-selective JAKi to selective JAKi is feasible and safe, and that it may improve disease activity outcomes in patients who have failed to achieve low disease activity or remission with a previous JAKi.
- Olumiant (baricitinib) / Incyte, Eli Lilly
Safety of Baricitinib for COVID-19 Related Hyperinflammation in Pediatric Patients: A Large Tertiary Care Center Experience (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_4018;
Children with Delta-variant associated hyperinflammation tolerated adjunctive treatment with baricitinib with a lower-than-expected adverse event and cessation rate. Additional data from other centers may be necessary to understand the role of JAK inhibition in enhancing the survival of children with severe COVID pneumonias and inflammation.
- dexamethasone / Generic mfg.
Generation of a Human 3D in Vitro Bone Model That Mimics Glucocorticoid-induced Osteoporosis (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3985;
Additional data from other centers may be necessary to understand the role of JAK inhibition in enhancing the survival of children with severe COVID pneumonias and inflammation. Ultimately, we will obtain an in vitro 3D co-culture of osteoblasts/osteoclasts simulating human native bone, which will be treated with dexamethasone to mimic key aspects of GIOP in vitro .
- methotrexate / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
Anti-PM/Scl Autoantibodies in Juvenile Myositis Are Associated with a Distinct Phenotype Resembling Anti-synthetase Syndrome (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3949;
Patients with anti-PM/Scl Abs, compared to those with anti-ARS Abs, were not Black, had an ANA with nucleolar pattern, and less frequently were positive for anti-Ro52 Abs. Acknowledgements: Intramural Research Program of NIAMS and NIEHS of the NIH.
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Stelara (ustekinumab) / J&J, Cosentyx (secukinumab) / Novartis
A Novel Inhibitory Pathway of Synovial Inflammation Exerted by Glucocorticoids and TNF Inhibitors Through LAG-3 Up-Regulation (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3764;
Within the tested anti-rheumatic drugs, this activity was exclusively mediated by GCs and to a lesser extent by a TNF inhibitor. GCs reduced the total SFMCs cell growth in culture and concomitantly up-regulated LAG-3, mainly on monocytes.
- dexamethasone / Generic mfg.
Therapeutic Effect of ICAM-1 Mimic on Experimental Axial Spondyloarthritis (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3709;
Follow-up studies will examine pharmacokinetics and pharmacodynamics of the compound. This is promising data for application of this ICAM-1 mimic as a new therapeutic option for axSpA.
- cenerimod (ACT-334441) / Idorsia
Successful Treatment of Rheumatoid Arthritis in Mice Using Cenerimod, a Selective Modulator of the S1P1 Receptor, Demonstrates the Potential Benefits of S1P1 Receptor Immunomodulation for Rheumatic Diseases (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3703;
P3
In particular, the reduction of dendritic cell migration suggests cenerimod may modulate antigen presentation, which could have implications for the treatment of autoimmune diseases. Our findings suggest that cenerimod can effectively disrupt multiple nodes of a vicious circle of pathogenesis associated with rheumatic diseases like RA.
- dexamethasone / Generic mfg., bleomycin / Generic mfg.
Macrophages Regulate Adipocyte Differentiation and Proliferation in Skin Fibrosis (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3071;
Our findings suggest that cenerimod can effectively disrupt multiple nodes of a vicious circle of pathogenesis associated with rheumatic diseases like RA. To assess the effect of M
- RCI002 / RudaCure
The Analgesic Effect of RC-0165, a TRPV1 Antagonist, for Osteoarthritis Pain (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_2969;
In vivo, pain-related behavioral effects were compared to RC-0165 and triamcinolone acetonide (TA)as positive control in a MIA-induced OA rat model, which was assessed using Von Frey, Hargreaves, open field, and rotarod tests. The results of our study suggest that RC-0165 may be a promising approach to significantly reduce OA pain compared to TA by suppressing pain signals mediated by TRPV1 effects of RCI002 compare to TA for OA
- Zilretta (triamcinolone acetonide ER) / Pacira
Extended-Release versus Immediate-Release Triamcinolone Acetonide for Osteoarthritis of the Knee with Comorbid Diabetes Type 2 Diabetes Mellitus: A Post Hoc Analysis (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_2954;
P2
Glucose management is expected to improve with TA-ER compared with TA-IR because of the increased percentage of time in the target range. Lower and more controlled glucose spikes may lead to fewer short-term hyperglycemia-related adverse events for patients receiving TA-ER versus TA-IR.
- Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB
Certolizumab-pegol, Abatacept, Tocilizumab or Active Conventional Therapy in Early Rheumatoid Arthritis: 48 Week Patient-reported Outcomes of the NORD-STAR Trial (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_2898;
P4
Lower and more controlled glucose spikes may lead to fewer short-term hyperglycemia-related adverse events for patients receiving TA-ER versus TA-IR. In this investigator-initiated, randomized, open-label study (NCT01491815), patients with treatment-na
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Long Term Safety and Predictors of Serious Infections Among Patients with Systemic Lupus Erythematosus Treated with Rituximab: Audit from a Single Center Biologic Registry (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_2687;
More than 50% of them occur after 1 year of RTX administration. Infections arise from common and rare opportunistic organisms.
- Krystexxa (pegloticase) / Amgen
Treatment-emergent Major Adverse Cardiovascular and Thromboembolic Events Were Infrequent During Pegloticase Therapy: Pooled Clinical Trial Findings (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_2371;
All events occurred within the 120 days of flare when pts were at higher risk. 3,4 Of note, pts with TE flares had higher pre-treatment flare rates than those without.
- MRT-6160 / Monte Rosa Therap
A VAV1-Directed Molecular Glue Degrader, MRT-6160, Reduces Joint Inflammation in a Collagen-Induced Arthritis Autoimmune Disease Model (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_2212;
3,4 Of note, pts with TE flares had higher pre-treatment flare rates than those without. In positive control groups, mice were administered either 1 mg/kg dexamethasone (daily via intraperitoneal injection) or 500
- Actemra IV (tocilizumab) / Roche, JW Pharma
Risk of Gastrointestinal Perforation Among Patients with Giant Cell Arteritis Who Received Tocilizumab (Room 6F/6C; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_2067;
When compared with steroid treatment, tocilizumab exposure was not associated with an increased risk of GI perforation. Risk factors for GI perforation included a history of diverticulitis and intravenous methylprednisolone use.
- methotrexate / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
Myositis-associated Autoantibodies in Juvenile Myositis Are Associated with Severe Disease Features and Mortality (Room 7A-B; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_1814;
Future prospective studies are needed to determine whether early detection of MAAs may improve outcomes for patients with juvenile myositis. Acknowledgements: Intramural Research Program of NIAMS and NIEHS of the NIH.
- Tavneos (avacopan) / Kissei, Amgen, Otsuka
Real-world Experience with Avacopan in ANCA Vasculitis: A Multi-center Retrospective Cohort Analysis (Ballroom 20D; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_1757;
Acknowledgements: Intramural Research Program of NIAMS and NIEHS of the NIH. Rituximab plus cyclophosphamide was the most common induction regimen (49%), followed by rituximab only (46%)...The cumulative dose of IV methylprednisolone was 2.4 g (
- Low vs. High Initial Oral Glucocorticoid Dose for Lupus Nephritis Induction Treatment: A Pooled Analysis of Randomized Controlled Clinical Trials (Ballroom 20D; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_1659;
Serious adverse events were less frequent in patients receiving low dose initial GC, although other study-specific considerations may factor in that association. These findings support the use of lower oral GC doses in LN treatment.
- || fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
Retrospective data, Review, Journal, Monotherapy: Efficacy and safety of fluticasone propionate/salmeterol and fluticasone propionate monotherapy in step-up treatment of childhood asthma: A systematic review and meta-analysis. (Pubmed Central) - Sep 23, 2023
Both FSC and FP alone are viable options for the initial selection of step-up treatment in asthmatic children. While, FSC treatment demonstrates a greater likelihood of reducing asthma exacerbations which is particularly important for reducing the personnel, social and economic burden in children requiring step-up asthma treatment.
- | Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute
Biomarker, Journal, IO biomarker: Venetoclax in biomarker-selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety. (Pubmed Central) - Sep 23, 2023
P1/2
Evaluation of the exposure-safety relationships demonstrated a lack of a relationship between venetoclax exposures (AUC ) and grade ?3 infections, grade ?3 neutropenia, grade ?3 treatment-emergent adverse events or any grade serious treatment-emergent adverse events. These findings support further study of venetoclax at 800
- | methylprednisolone acetate / Generic mfg.
Journal: Corticosteroid Injections for Symptomatic Treatment of Osteoarthritis of the Knee: A Pilot Blinded Randomized Trial. (Pubmed Central) - Sep 23, 2023
P=N/A
Corticosteroid injections demonstrated clinically meaningful improvements in KOA symptoms over 12?weeks of follow-up. These data support larger studies to better quantify short-term benefits.
- | dexamethasone / Generic mfg.
Journal: Green synthesis of metal-organic framework loaded dexamethasone on wood aerogels for enhanced cranial bone regeneration. (Pubmed Central) - Sep 23, 2023
In this study, for the first time, a simple but effective one-pot method for developing a novel zeolitic imidazolate framework-8 with different concentrations of dexamethasone was developed. These findings illustrate that the novel scaffold has a significant positive impact on osteogenic differentiation in vitro and repairs defects in vivo, suggesting that it can be used in bone tissue engineering.
- | dexamethasone / Generic mfg.
Journal: Increased risk of vertebral fractures in patients with mild autonomous cortisol secretion. (Pubmed Central) - Sep 22, 2023
These findings illustrate that the novel scaffold has a significant positive impact on osteogenic differentiation in vitro and repairs defects in vivo, suggesting that it can be used in bone tissue engineering. Women and men with AI and MACS are at higher risk of VFx.
- | dexamethasone / Generic mfg.
Journal: A comment on Preoperative dexamethasone administration in hepatectomy of 25-minute intermittent Pringle's maneuver for hepatocellular carcinoma: a randomized controlled trial. (Pubmed Central) - Sep 22, 2023
Women and men with AI and MACS are at higher risk of VFx. No abstract available
- || Review, Journal, IO biomarker: Therapeutic approaches for cholestatic liver diseases: the role of nitric oxide pathway. (Pubmed Central) - Sep 22, 2023
This study summarizes the latest scientific data about the bile acid signaling pathway, the neutrophil chemotaxis recruitment process during cholestasis, and the role of NO in cholestasis liver diseases. Literature review directed us to propose that suppression of NO and its related pathways could be a therapeutic option for preventing or treating cholestatic liver diseases.
- | Korlym (mifepristone) / Corcept Therap, miricorilant (CORT118335) / Corcept Therap, Mifeprex (mifepristone) / Danco Laboratories
Preclinical, Journal: Glucocorticoid receptor modulator CORT125385 alleviates diet-induced hepatosteatosis in male and female mice. (Pubmed Central) - Sep 22, 2023
In this study, we set out to evaluate the novel glucocorticoid receptor modulator CORT125385, an analogue of the previously studied miricorilant but without mineralocorticoid receptor binding activity...In vivo, CORT125385 treatment did not influence PR-responsive gene expression in the oviduct, while mifepristone treatment strongly influenced these genes in the oviduct, thus excluding in vivo PR cross-reactivity of CORT125385 at a therapeutically active dose. We conclude that CORT125385 is a promising glucocorticoid receptor modulator that effectively reduces liver steatosis in male and female mice without affecting other steroid receptors at doses that lower hepatic lipid content.
- || Rizaben (tranilast) / Kissei, Nuon Therapeutics
Biomarker, Review, Journal, Tumor microenvironment: Strategy of targeting the tumor microenvironment via inhibition of fibroblast/fibrosis remodeling new era to cancer chemo-immunotherapy resistance. (Pubmed Central) - Sep 22, 2023
Consistent to many repurposing drugs such as pirfenidone, metformin, losartan, tranilast, dexamethasone and pentoxifylline are used to decrease immune-suppression by abrogation of TME inhibitory signal that stimulates the immune system and increases efficiency and reduces resistance to chemotherapy drugs. To overcome immunosuppression based on fibroblast/fibrosis remodeling, in this review, we focus on inhibitory signal transduction, which is the physical barrier, alleviates mechanical stress and prevents mechano-metabolic activation.
- || dexamethasone / Generic mfg.
Clinical, Journal, Surgery: CORR Insights (Pubmed Central) - Sep 22, 2023
To overcome immunosuppression based on fibroblast/fibrosis remodeling, in this review, we focus on inhibitory signal transduction, which is the physical barrier, alleviates mechanical stress and prevents mechano-metabolic activation. No abstract available
- | Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial completion date, Trial primary completion date: NCI-2017-00596: Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 22, 2023
P2, N=80, Recruiting, Sponsor: M.D. Anderson Cancer Center
No abstract available Trial completion date: Nov 2023 --> Nov 2026 | Trial primary completion date: Nov 2023 --> Nov 2026
- || Ninlaro (ixazomib) / Takeda, mezigdomide (CC-92480) / BMS
New P1/2 trial: Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Sep 22, 2023
P1/2, N=34, Not yet recruiting, Sponsor: Kathleen Dorritie
- | Abecma (idecabtagene vicleucel) / BMS, 2seventy bio, mezigdomide (CC-92480) / BMS
Enrollment open: Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma (clinicaltrials.gov) - Sep 22, 2023
P1, N=15, Recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Nov 2023 --> Nov 2026 | Trial primary completion date: Nov 2023 --> Nov 2026 Not yet recruiting --> Recruiting
- || Elrexfio (elranatamab-bcmm) / Pfizer
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy: MagnetisMM-9: A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment (clinicaltrials.gov) - Sep 22, 2023
P2, N=86, Active, not recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: May 2026 --> May 2025 | Trial primary completion date: Aug 2024 --> Jun 2023
- | flotetuzumab (MGD006) / MacroGenics
Enrollment closed, Enrollment change, Metastases: Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies (clinicaltrials.gov) - Sep 22, 2023
P1, N=13, Active, not recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting | Trial completion date: May 2026 --> May 2025 | Trial primary completion date: Aug 2024 --> Jun 2023 Recruiting --> Active, not recruiting | N=40 --> 13
- Keytruda (pembrolizumab) / Merck (MSD)
To Close or Not to Close: A Case of Multisystem Immune Checkpoint Inhibitor Toxicity and PFO (Zone 4, Science and Technology Hall, Level 2) - Sep 21, 2023 - Abstract #AHA2023AHA_7345;
In this case, persistent hypoxemia despite treatment for ICI toxicity unmasked a large PFO requiring closure. A multisystem approach should be used to assess suspected ICI myocarditis.
- dexamethasone / Generic mfg.
Targeting Lipid Nanoparticles to the Blood Brain Barrier to Ameliorate Acute Ischemic Stroke (Zone 4, Science and Technology Hall, Level 2) - Sep 21, 2023 - Abstract #AHA2023AHA_6834;
VCAM/IL-10 mRNA LNP also achieved a 100% survival rate (E) and elevated plasma levels of IL-10. In conclusion, VCAM-targeted lipid nanoparticles provide a novel platform for effectively concentrating drugs within the compromised BBB of the penumbra, thereby improving the outcomes of AIS.
- |||| Breztri Aerosphere (budesonide/formoterol fumarate/glycopyrronium) / AstraZeneca
Trial primary completion date: A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Sep 21, 2023
P3, N=558, Active, not recruiting, Sponsor: AstraZeneca
In conclusion, VCAM-targeted lipid nanoparticles provide a novel platform for effectively concentrating drugs within the compromised BBB of the penumbra, thereby improving the outcomes of AIS. Trial primary completion date: Sep 2023 --> Mar 2024
- | Decadron (dexamethasone) / Merck (MSD)
Trial primary completion date: DEXA-REFINE: Efficacy of DEXamethasone in Patients With Acute Hypoxemic REspiratory Failure Caused by INfEctions (clinicaltrials.gov) - Sep 21, 2023
P4, N=980, Recruiting, Sponsor: Dr. Negrin University Hospital
Trial primary completion date: Sep 2023 --> Mar 2024 Trial primary completion date: Sep 2023 --> Dec 2023
- | hydrocortisone / Generic mfg.
Trial completion date, Trial primary completion date: HYVAPRESS: HYdrocortisone and VAsopressin in Post-RESuscitation Syndrome (clinicaltrials.gov) - Sep 21, 2023
P3, N=380, Recruiting, Sponsor: Assistance Publique - H
Trial primary completion date: Sep 2023 --> Dec 2023 Trial completion date: May 2023 --> Aug 2024 | Trial primary completion date: May 2023 --> Jul 2024
- | Yonsa (abiraterone acetate) / Churchill Pharma, Sun Pharma, Erleada (apalutamide) / J&J
Trial completion date, Trial primary completion date, Metastases: Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer (clinicaltrials.gov) - Sep 21, 2023
P2, N=60, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: May 2023 --> Aug 2024 | Trial primary completion date: May 2023 --> Jul 2024 Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Oct 2023 --> Oct 2024
- | New trial, IO biomarker: Effect of Azole/Echinocandin Use on Tacrolimus Pharmacokinetics (clinicaltrials.gov) - Sep 21, 2023
P=N/A, N=507, Completed, Sponsor: LI YAN
- | dexamethasone injection / Generic mfg.
New trial: P6 Acupressure Band for Prevention of Postoperative Nausea and Vomiting in Children (clinicaltrials.gov) - Sep 21, 2023
P=N/A, N=64, Completed, Sponsor: Universiti Kebangsaan Malaysia Medical Centre
- | dexamethasone injection / Generic mfg., granisetron intravenous / Generic mfg.
New P4 trial: Palonosetron vs Combination of Granisetron and Dexamethasone in Preventing PONV in Laparoscopic Cholecystectomy. (clinicaltrials.gov) - Sep 21, 2023
P4, N=134, Completed, Sponsor: Universiti Kebangsaan Malaysia Medical Centre
- | dexamethasone injection / Generic mfg.
New P4 trial: DEPOS: Effect of Dexamethason on Postimplantation Syndrome After EVAR (clinicaltrials.gov) - Sep 21, 2023
P4, N=158, Not yet recruiting, Sponsor: Centro Hospitalar de Lisboa Central
- | methylprednisolone acetate / Generic mfg.
New P3 trial: Ultrasound-guided Dextrose Injection Versus Dextrose With Methylprednisolone in Carpal Tunnel Syndrome (clinicaltrials.gov) - Sep 21, 2023
P3, N=70, Recruiting, Sponsor: General and Veteran Hospital Croatian Pride Knin
- | Abecma (idecabtagene vicleucel) / BMS, 2seventy bio, mezigdomide (CC-92480) / BMS
New P1 trial: Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma (clinicaltrials.gov) - Sep 21, 2023
P1, N=15, Not yet recruiting, Sponsor: City of Hope Medical Center
- | prednisone / Generic mfg.
Enrollment open: Intra-Tympanic Steroid With PRP Combination in Sensorineural Hearing Loss and Tinnitus. (clinicaltrials.gov) - Sep 21, 2023
P1, N=70, Recruiting, Sponsor: CMH RWP Combined Military Hospital RWP: Rawalpindi
Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Oct 2023 --> Oct 2024 Not yet recruiting --> Recruiting
- | mometasone furoate oral (ESO-101) / EsoCap AG
Enrollment closed, Trial completion date, Trial primary completion date: A Study to Investigate the Efficacy and Tolerability of ESO-101 in Patients With Eosinophilic Esophagitis (clinicaltrials.gov) - Sep 21, 2023
P2, N=43, Active, not recruiting, Sponsor: EsoCap AG
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> Oct 2023 | Trial primary completion date: Dec 2021 --> Oct 2023
- | dexamethasone / Generic mfg.
Trial completion, Surgery, Bariatric surgery: Preoperative Dexamethasone to Improve Quality of Recovery After Laparoscopic Bariatric Surgery (clinicaltrials.gov) - Sep 21, 2023
P=N/A, N=60, Completed, Sponsor: Ondokuz May?s University
Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> Oct 2023 | Trial primary completion date: Dec 2021 --> Oct 2023 Recruiting --> Completed
- | budesonide / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Acupuncture Therapy for COVID-Related Olfactory Loss (clinicaltrials.gov) - Sep 21, 2023
P=N/A, N=32, Completed, Sponsor: Mayo Clinic
Recruiting --> Completed Active, not recruiting --> Completed | N=100 --> 32 | Trial primary completion date: Aug 2023 --> Apr 2023